Estrogen-progestin replacement therapy: Regulatory action needed

Breast Cancer Research

Volumn 4, Issue 6, 2002, Pages 222-223

  Pike, Malcolm C ^a   Ross, Ronald K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; Estrogen; Postmenopause; Progestin

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; PROGESTERONE DERIVATIVE;

ADULT; BREAST CANCER; CANCER RISK; DISEASE MARKER; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; REVIEW; TREATMENT OUTCOME;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTINS;

EID: 0036437060     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr550     Document Type: Review

References (13)

1. Schairer C: Progesterone receptors - animal models and cell signalling in breast cancer: implications for breast cancer of inclusion of progestins in hormone replacement therapies. Breast Cancer Res 2002, 4:244-248.
2. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288: 321-333.
3. Henderson BE, Pike MC, Ross RK, Mack TM, Lobo RA: Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril 1988, 49(suppl):9-15.
4. Key TJA, Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988, 24:29-43.
5. Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C: Combined oestrogen-progestogen replacement therapy and breast cancer risk [letter]. Lancet 1992, 340:1044.
6. Shoupe D, Meme D, Mezrow G, Lobo RA: Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. N Engl J Med 1991, 325:1811-1812.
7. Varila E, Wahlstrom T, Rauramo I: A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001, 76: 969-973.
8. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV: Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes. Fertil Steril 1994, 62:485-490.
9. Fanchin R, de Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R: Transvaginal administration of progesterone. Obstet Gynecol 1997, 90:396-401.
10. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR: Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994, 83:693-700.
11. Williams DB, Voigt BJ, Yao SF, Schoenfeld MJ, Judd HL: Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol 1994, 84:787-793.
12. Pike MC, Ross RK: Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000, 65:659-664.
13. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskaas C, Bush T, Barrett-Connor E: Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999, 130:262-269.